

PROVIDER QUICK POINTS

PROVIDER INFORMATION



April 14, 2021

MHCP Pharmacy Benefit Exclusion for Select Medications

Effective April 14, 2021, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

| Drug Name |
|--|
| Amondys 45 (casimersen) injection |
| Breyanzi® (lisocabtagene maraleucel) suspension for intravenous infusion |
| Cosela™ (trilaciclib) injection |
| Evkeeza™ (evinacumab-dgnb) injection |
| Margenza™ (margetuximab-cmkb) injection |
| Olinvyk™ (oliceridine) injection |
| Pepaxto® (melphalan flufenamide) injection |
| Riabni™ (rituximab-arrr) injection |
| Xaracoll® (bupivacaine HCl) implant |

Products Impacted

This exclusion applies to the following Minnesota Health Care Programs:

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. Please contact provider services at **(651) 662-5200** or **1-800-262-0820** for all other questions.